MedPath

Effect of EIT-guided PEEP Titration on the Prognosis of Patients with Moderate to Severe ARDS

Not Applicable
Completed
Conditions
Clinical Outcomes
Interventions
Device: electrical impedance tomography
Registration Number
NCT05207202
Lead Sponsor
Southeast University, China
Brief Summary

Acute respiratory syndrome distress (ARDS) is a clinical common syndrome with high mortality. Mechanical ventilation (MV) is the cornerstone of management of ARDS but can lead to ventilator-induced lung injury. Positive end-expiratory pressure (PEEP), as one of main component of MV, has been widely used in the clinical practice. However, the PEEP selection is still a difficult problem for moderate to severe ARDS patients. EIT, an imaging tool evaluating the regional ventilation distribution at the bedside, can achieve the individual PEEP selection for all mechanically ventilated patients. This article compared the effect of PEEP titrated guided by EIT with fraction of inspired oxygen (FiO2)-PEEP table on the clinical outcomes.

Detailed Description

This is a prospective, multicenter, single-blind, parallel-group, adaptive randomized controlled trial (RCT) with intention-to-treat analysis which aims to determine the effects of PEEP setting guided by EIT on the clinical outcomes for moderate or severe ARDS patients ventilated with lung protective ventilation strategy. Adult patients with moderate to severe ARDS less than 72 hours after diagnosis will be included in this study. Patients in the intervention group will receive PEEP titrated by EIT with a stepwise decrease PEEP trial, whereas patients in the control group will select PEEP based on the FiO2-PEEP table. Other ventilator parameters will be set according to the ARDSnet strategy. The primary outcome is 28-day mortality. The secondary outcomes include ventilator-free days and shock-free days at day 28, length of ICU and hospital stay, the rate of successful weaning, proportion requiring rescue therapies, compilations, respiratory variables, and Sequential Organ Failure Assessment (SOFA). This study will also perform the interim analysis and subgroup analysis.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
190
Inclusion Criteria
  1. Age≥18 years
  2. Moderate-to-severe ARDS, defined by the ARDS Definition Task Force in the Berlin definition (partial pressure of arterial oxygen [PaO2]:FiO2 ratio ≤200 mmHg with a PEEP ≥5 cmH2O)
  3. Diagnosis of ARDS less than 72 hours
Exclusion Criteria
  1. Expected to be mechanically ventilated for less than 48 hours
  2. Severe chronic respiratory diseases requiring long-term home oxygen therapy or noninvasive MV
  3. Undrained pneumothorax or subcutaneous emphysema
  4. Undergoing extracorporeal membrane oxygenation (ECMO) before enrollment
  5. Contraindication to the use of EIT (pacemaker, automatic implantable cardioverter defibrillator, and implantable pumps)
  6. Severe neuromuscular disease
  7. Hemodynamic instability
  8. Contraindications to hypercapnia, such as intracranial hypertension or acute coronary syndrome
  9. Severe other organs dysfunction with a low expected survival (7 days) or palliative care
  10. Solid organ or hematologic tumors with the expected survival time less than 30 days
  11. Participating in other clinical trials within 30 days
  12. Pregnancy
  13. Refusal to sign the informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
ARDSNet-PEEP strategyelectrical impedance tomographyPEEP will be set according to the low FiO2-PEEP table to keep the oxygenation goals: SpO2 between 88% and 95%, and PaO2 between 55mmHg and 80mmHg.
EIT-PEEP strategyelectrical impedance tomographyPatients will receive PEEP titrated by EIT with a stepwise decrease PEEP trial
Primary Outcome Measures
NameTimeMethod
28-day mortalityat day 28

mortality in Day 28

Secondary Outcome Measures
NameTimeMethod
Rate of pneumothoraxday 28

Rate of pneumothorax

Sequential Organ Failure Assessment (SOFA) score at the time of enrollmentat the time of enrollment

SOFA range from three to eight. The higher the score, the worse the prognosis

Shock-free days at day 28at day 28

Shock-free days at day 28

number of shock and gastrointestinal hemorrhageday 28

shock, and gastrointestinal hemorrhage

respiratory rateup to 7 days

respiratory rate

VFDs at day 28at day 28

defined as the number of days between successful weaning from MV and day 28 after study enrollment

Length of ICU stayup to 24 months

the survival rate(survival/total) during ICU stay

Length of hospital stayup to 24 months

the survival rate(survival/total) during hospital stay

The rate of successful weaningat day 28

Proportion of people who are not dependent on ventilator ventilation

Proportion requiring rescue therapiesday 28

Proportion of people who require rescue therapies

driving pressureday 0, day 1, day 2, day 3, day 7

measurement as one index of respiratory compliance at day 0, 1, 2, 3, and 7 from enrollment

Blood pressure at day D1, 2, 3, and 7 from enrollmentup to 24 months

Both systolic and diastolic pressure at day D1, 2, 3, and 7 from enrollment

Trial Locations

Locations (5)

the First Affiliated Hospital of Guangzhou Medical University, Department of Critical Care Medicine

🇨🇳

Guangzhou, Guangdong, China

Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University

🇨🇳

Nanjing, Jiangsu, China

Department of Critical Care Medicine, Renji Hospital

🇨🇳

Shanghai, Shanghai, China

Department of Critical Care Medicine, Zhongshan Hospital of Fudan University

🇨🇳

Shangha, Shangha, China

Department of ICU, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath